Month: March 2025

Press ReleaseNicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development UpdateMore patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost New analysis provides additional data demonstrating differentiation of NCX 470 Development activities on track for U.S. New Drug Application submission targeted in H1 2026March 3, 2025 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided details of a poster presentation highlighting additional pre-planned analysis from the NCX 470 Mont Blanc Phase 3 clinical trial at the 2025 American Glaucoma Society (AGS) Annual Meeting, one of the key scientific events in vision research, which was held on February...

P R E S S  R E L E A S EStockholm, March 3, 2025 STOCKHOLM, SWEDEN – BTS Group AB (publ), a leading global consultancy specializing in strategy execution, change, and people development, has agreed to acquire Sounding Board, a technology-based leader in scalable, high-impact coaching solutions driving transformational leadership development. “With this acquisition, BTS can leapfrog its current technology and operations with the integration of a team and platform that is considerably more productive and ready-to-scale globally than our current technology. The acquisition allows us to create and take to market a very differentiated offering and to faster expand BTS’ current USD 40 million coaching services, taking advantage of the growing USD 7 billion coaching market, and to increase our margins,” says Jessica Skon, CEO of BTS Group. Founded...

HOUSTON, March 03, 2025 (GLOBE NEWSWIRE) — VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) (“Vaalco” or the “Company”) announced that it has farmed into the CI-705 block offshore Côte d’Ivoire. Vaalco will become operator of the block with a 70% working interest and a 100% paying interest though a commercial carry arrangement and is partnering with Ivory Coast Exploration Oil & Gas SAS and PETROCI. The CI-705 block is located in the prolific Tano basin and is approximately 70 kilometers (“km”) to the west of Vaalco’s CI-40 Block, where the Baobab and Kossipo oil fields are located, and 60 km west of ENI’s recent Calao discovery. Block CI-705 covers approximately 2,300 km2 and is lightly explored with three wells drilled to date on the block. The water depth across the block ranges from zero to 2,500 meters. Vaalco has invested $3...

What you need to know:Verizon Business and Accenture will help customers across all industries and businesses of all sizes become cyber resilient. New advanced services will help companies identify security vulnerabilities and detect, respond to and recover from cyberattacks and will be integrated with Verizon’s portfolio of network solutions.  The partnership will focus on the most pressing areas of risk: identity and access management (IAM), managed extended detection and response (MxDR) and cyber risk services.NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — To address the rapidly evolving cybersecurity landscape, Verizon Business and Accenture today announced a strategic partnership to accelerate the development and delivery of advanced cybersecurity solutions. The agreement aims to help businesses of all sizes mitigate a range...

EXOSENS MAKES FIRST US INVESTMENT IN NIGHT VISION PRODUCTION CAPACITY TO ADDRESS GROWING DEMAND AND BENEFIT FROM NEW OPPORTUNITIES PRESS RELEASEMÉRIGNAC, FRANCE – MARCH, 3rd 2025In response to increasing demand, Exosens will invest €20M over the next two years to expand production capacity in both Europe and the U.S. This investment will establish Exosens’ first U.S. manufacturing site for producing “Made in America” image intensifier tubes It strengthens Exosens’ position to capture a larger share of the world’s largest market, which represents 45% of the global market and is set for strong growth in both commercial and defense sectorsThe global night vision market is benefiting from growing demand, driven by increasing defense budgets and the need for armies worldwide to enhance their night fighting...

Beijing, March 02, 2025 (GLOBE NEWSWIRE) — AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, today announced the pricing of its public offering of 16,390,000 Class A ordinary shares and accompanying warrants to purchase up to an aggregate of 16,390,000 Class A ordinary shares at a combined public offering price of $0.33. The warrants will expire on the fifth anniversary from the date of issuance, will be exercisable immediately at an initial exercise price of $0.33 per share, subject to adjustment upon a one-time reset on the Reset Date (as described in the warrants), and subject to a floor price described therein. The warrants may also be exercised on an alternative cashless basis...

TOKYO, March 02, 2025 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced it has hired Shimpei Kanzaki as a Managing Director and Head of Japan Global Wealth. Kanzaki brings more than 20 years’ experience in alternative investments, private markets and the wealth management industry, and will report to Edward Moon, Partner and Head of Asia Pacific Global Wealth for Apollo. Moon said, “We are pleased to welcome Shimpei, who brings to Apollo significant industry experience and a proven track record of business building in the Japan wealth market. Following our successful expansion in Hong Kong and Singapore, we look forward to growing in Japan, expanding our product suite and partnering with Japanese distributors across wealth channels.” Apollo Partner and Chief Client and Product Development Officer Stephanie Drescher added, “Japan...

First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergiesBasel, 2 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide further evidence supporting the role of Xolair® (omalizumab) for the treatment of one or more food allergies. Stage 2 of the OUtMATCH study showed Xolair was more effective with fewer side effects than multi-allergen oral immunotherapy (OIT) in the first-ever head-to-head trial comparing the two treatment approaches. OIT involves ingesting the food allergen,...